 | Multiple Myeloma Treatment: Experimental drug combination ‘encouraging’ in relapsed multiple myeloma
|  |
|---|
| | SAN DIEGO–When the targeted drug bortezomib stops working in patients with advanced multiple myeloma, the patients survive only an average of five months longer. But a phase 2 clinical trial has show... [more]
| |
| Drug for Multiple Myeloma Demonstrated to Significantly Extend Disease-Free Survival
| |
|---|
| | Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, showed that patients who received the oral drug lenalidomide (... [more]
| |
| Multiple Myeloma: New Drug Shows Positive Responses, Low Side-Effects in Clinical Trial
| |
|---|
| | The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, ... [more]
| |
| New Multiple Myeloma Drug Proves More Potent than Thalidomide
| |
|---|
| | A designer drug significantly less toxic than thalidomide has shown impressive activity in prolonging survival of patients with advanced multiple myeloma, report researchers from Dana-Farber Cancer In... [more]
| |
| Velcade: A New Strategy Treating Multiple Myeloma
| |
|---|
| | Velcade is a new drug that acts in a different way from typical chemotherapy drugs. It is rapidly becoming a standard treatment for patients with multiple myeloma who have relapsed after other treatme... [more]
| |
| Multiple Myeloma Updates
| |
|---|
| | The role of stem cell transplantation in the management of multiple myeloma has been controversial. For many the impression is the procedure is not worse than standard chemotherapy, and possibly bette... [more]
| |
___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
|
